Immune-Suppressive Mechanisms and Cancer: Understanding the Implications, Paradoxes, and Burning Questions -- Mechanisms of Tumor-Associated T-Cell Tolerance -- Contribution of B7-H1/PD-1 Co-inhibitory Pathway to T-Cell Dysfunction in Cancer -- Regulatory T Cells in Cancer -- Cancer-Induced Signaling Defects in Antitumor T Cells -- Immunobiology of Dendritic Cells in Cancer -- Macrophages and Tumor Development -- Myeloid-Derived Suppressor Cells in Cancer -- Signaling Pathways in Antigen-Presenting Cells Involved in the Induction of Antigen-Specific T-Cell Tolerance -- Arginine Availability Regulates T-Cell Function in Cancer -- Protein-Glycan Interactions in the Regulation of Immune Cell Function in Cancer: Lessons from the Study of Galectins-1 and -3 -- Role of Reactive Oxygen Species in T-Cell Defects in Cancer -- Tumor Stroma and the Antitumor Immune Response. Tumor Induced Immune Suppression: Mechanisms and Therapeutic Reversal focuses on the critical question of tumor biology: "Why can tumors escape immune system control?" It also addresses one of the most important problems within the field of clinical oncology: the lack of efficient cancer vaccines. Edited by Dmitry Gabrilovich and Andy Hurwitz, the book is the first attempt at a systematic and comprehensive analysis of the various immunosuppressive mechanisms in cancer. This analysis includes information on: Different surface molecules that mediate T-cell suppression in cancer; The specific roles of dendritic cells, macrophages, and myeloid-derived suppressor cells in tumor non-responsiveness; The contribution of regulatory T cells in the inability of immune systems to mount antitumor response; The role of T-cell signaling and different metabolic pathways in tumor-associated immune suppression. This volume connects a multitude of different immunosuppressive mechanisms into one cohesive picture. Most of the chapters not only describe the biological phenomena, but also suggest specific approaches to their correction. This book should be of high interest for researchers in the fields of tumor immunology and general immunology, as well as for those who are involved in clinical oncology and cancer immunotherapy.